BAAR, Switzerland — Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq®), gemcitabine and nab-paclitaxel (gem/nab-pac) as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). PANOVA-4 met its pre-specified primary endpoint, achieving a statistically significant improvement...

NEWTON, Mass. — Abcuro, Inc., a clinical stage biotechnology company, today presented results at the 6th Global Conference on Myositis (GCOM) meeting, being held March 23-26, 2026 in Lisbon, Portugal from the Phase 2/3 MUSCLE clinical study of ulviprubart (ABC008), an investigational monoclonal antibody in development for the treatment of patients...

ALBANY, N.Y. & SHANGHAI, China — Drug Farm today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to DF-003, the company’s investigational small molecule inhibitor targeting ALPK1, for the treatment of patients with ROSAH syndrome, a rare, genetically driven systemic autoinflammatory disease with...